Cargando…

Annotating MYC oncogene status with (89)Zr-transferrin imaging

A non-invasive technology that quantitatively measures the activity of oncogenic signaling pathways could broadly impact cancer diagnosis and treatment using targeted therapies. Here we describe the development of (89)Zr-desferrioxamine transferrin ((89)Zr-Tf), a novel positron emission tomography (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holland, Jason P., Evans, Michael J., Rice, Samuel L., Wongvipat, John, Sawyers, Charles L., Lewis, Jason S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521603/ https://www.ncbi.nlm.nih.gov/pubmed/23001181 http://dx.doi.org/10.1038/nm.2935

Ejemplares similares

Applying (89)Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins
por: Doran, Michael G., et al.
Publicado: (2016)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Microfluidic Preparation of (89)Zr-Radiolabelled Proteins by Flow Photochemistry
por: Earley, Daniel F., et al.
Publicado: (2021)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Automated light-induced synthesis of (89)Zr-radiolabeled antibodies for immuno-positron emission tomography
por: Klingler, Simon, et al.
Publicado: (2022)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas
por: Herrero Alvarez, Natalia, et al.
Publicado: (2023)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

PET Imaging of Acidic Tumor Environment With (89)Zr-labeled pHLIP Probes
por: Bauer, David, et al.
Publicado: (2022)

Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
por: Escorcia, Freddy E., et al.
Publicado: (2018)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
por: Clegg, Nicola J., et al.
Publicado: (2011)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

Imaging EGFR and HER3 through (89)Zr-labeled MEHD7945A (Duligotuzumab)
por: McKnight, Brooke N., et al.
Publicado: (2018)

Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with (89)Zr-5B1
por: Houghton, Jacob L., et al.
Publicado: (2017)

Noninvasive Imaging of PSMA in Prostate Tumors with (89)Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
por: Viola-Villegas, Nerissa Therese, et al.
Publicado: (2014)

Pet imaging of cytotoxic human T cells using an 89Zr-labeled anti-CD8 minibody
por: Olafsen, Tove, et al.
Publicado: (2015)

(89)Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model
por: Stone, Logan D., et al.
Publicado: (2022)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Selective Hydrolysis of Transferrin Promoted by Zr-Substituted Polyoxometalates
por: Van Rompuy, Laura S., et al.
Publicado: (2020)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

Alternative Chelator for (89)Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
por: Deri, Melissa A., et al.
Publicado: (2014)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Development and evaluation of (89)Zr-trastuzumab for clinical applications
por: Mohammadpour-Ghazi, Fatemeh, et al.
Publicado: (2023)

The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of (89)Zr-DFO-Pertuzumab
por: Vivier, Delphine, et al.
Publicado: (2020)

(89)Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
por: Chang, Albert J., et al.
Publicado: (2012)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

(89)Zr-Cobalamin PET Tracer: Synthesis, Cellular Uptake, and Use for Tumor Imaging
por: Kuda-Wedagedara, Akhila N. W., et al.
Publicado: (2017)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

PET/CT Imaging of (89)Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys
por: Li, Wenping, et al.
Publicado: (2020)

Evaluation of Candidate Theranostics for (227)Th/(89)Zr Paired Radioimmunotherapy of Lymphoma
por: Abou, Diane S., et al.
Publicado: (2023)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

(89)Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
por: Kahts, Maryke, et al.
Publicado: (2023)

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
por: Huang, Chun-Hao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mpk13s0b5lmcqqgf0cagt78ro8